CN116675780B - Preparation of canine fibroblast growth factor 21 fusion protein and application thereof in treating atopic dermatitis - Google Patents
Preparation of canine fibroblast growth factor 21 fusion protein and application thereof in treating atopic dermatitis Download PDFInfo
- Publication number
- CN116675780B CN116675780B CN202310648161.0A CN202310648161A CN116675780B CN 116675780 B CN116675780 B CN 116675780B CN 202310648161 A CN202310648161 A CN 202310648161A CN 116675780 B CN116675780 B CN 116675780B
- Authority
- CN
- China
- Prior art keywords
- fgf
- atopic dermatitis
- mice
- growth factor
- fibroblast growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 title claims abstract description 29
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 title claims abstract description 28
- 206010012438 Dermatitis atopic Diseases 0.000 title claims abstract description 27
- 201000008937 atopic dermatitis Diseases 0.000 title claims abstract description 27
- 241000282465 Canis Species 0.000 title claims abstract description 17
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 14
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 230000009261 transgenic effect Effects 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 31
- 208000024891 symptom Diseases 0.000 abstract description 8
- 230000002757 inflammatory effect Effects 0.000 abstract description 5
- 230000004927 fusion Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 239000008103 glucose Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 10
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 201000004624 Dermatitis Diseases 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 229960001967 tacrolimus Drugs 0.000 description 7
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 206010070834 Sensitisation Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000008313 sensitization Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 206010014025 Ear swelling Diseases 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101100120063 Homo sapiens FGF21 gene Proteins 0.000 description 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 206010024438 Lichenification Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 229940074608 allergen extract Drugs 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a preparation method of a canine fibroblast growth factor 21 fusion protein and application thereof in treating atopic dermatitis. The invention provides a canine fibroblast growth factor 21 (FGF 21) fusion protein, which consists of canine fibroblast growth factor 21 (FGF 21) and a fusion tag, wherein the fusion tag is TAT or R11 or Fc; the three FGF-21 fusion proteins obtained by the invention can effectively improve the symptom of the atopic dermatitis of mice and reduce the expression level of related inflammatory factors; the three FGF-21 recombinant fusion proteins provided by the invention can be used as potential drugs for treating canine atopic dermatitis.
Description
Technical Field
The invention relates to preparation of a canine fibroblast growth factor 21 fusion protein and application thereof in treating atopic dermatitis, belonging to the field of biotechnology.
Background
With the rising of the feeding amount of the pet dogs, the canine diseases are also more and more widely focused by people, and the increasingly developed industries and the aggravated pollution of living environment lead to the high incidence of allergic diseases of the dogs. Allergic diseases in dogs include atopic dermatitis, gastrointestinal inflammation and allergic reactions. Among them, canine Atopic Dermatitis (CAD) is widely prevalent worldwide, with up to 10% of dogs affected. Canine Atopic Dermatitis (AD) is a common hereditary inflammatory and pruritic allergic skin disease. Atopic dermatitis is seen in a very similar clinical presentation in different species, and unlike humans where respiratory symptoms may occur, dogs often remain in the cutaneous stage of the disease. However, many clinical and etiologic features are highly similar and CAD is often described as a model of human Atopic Dermatitis (AD). In clinical treatment, glucocorticoids, cyclosporine, oxatinib and the like are commonly used, and the medicines have great side effects after long-term use, and allergen immunotherapy with good treatment effect needs to detect the allergen of dogs and obtain allergen extracts, so that the method is complex in operation, poor in universality and difficult to use in a large amount. Therefore, there is a great clinical need for the development of anti-inflammatory drugs suitable for dogs, which have long-acting effects and less side effects, and which can treat atopic dermatitis.
Fibroblast growth factor21 (Fibroblast growth factor, FGF-21) is a member of the fibroblast growth factor family, which is of great interest because of its close association with glycolipid metabolism. In recent years, there have been studies showing that FGF-21 has anti-inflammatory effects in addition to the effects of combating obesity, improving insulin resistance and various metabolic diseases. FGF-21 can reduce inflammatory factors such as IL-1 beta, IL-6, TNF-alpha and the like in mouse serum, and inhibit the transcription and translation of NF-kappa B p.
FGF-21 has not been reported to have an ameliorating effect on canine atopic dermatitis. Therefore, the invention adopts a DNCB-induced atopic dermatitis mouse model to explore the pharmacodynamic effect of FGF-21 on canine atopic dermatitis. The laboratory finds that FGF-21-TAT, FGF-21-R11 and FGF-21-Fc can obviously reduce dermatitis score, improve dermatitis symptoms and effectively inhibit the expression of related inflammatory factors in animal models, and shows that the laboratory has the potential of treating atopic dermatitis diseases.
Disclosure of Invention
The invention aims to provide the preparation of a canine fibroblast growth factor 21 fusion protein and the application thereof in treating atopic dermatitis. The fusion protein consists of canine fibroblast growth factor 21 (FGF 21) and a fusion tag, wherein the fusion tag is TAT or R11 or Fc, and the fusion protein has important application in treating canine atopic dermatitis diseases.
Drawings
FIG. 1 identification of three FGF-21 fusion proteins after purification
FIG. 2 in vitro assay of three fusion protein Activity
FIG. 3 in vivo detection of three fusion protein Activity
FIG. 4 results of back H & E staining of AD mice
FIG. 5 results of H & E staining of ear of AD mice
FIG. 6 results of immunohistochemical analysis of TSLP protein in AD mouse tissue
FIG. 7 serum-related inflammatory factor ELISA results
Detailed Description
Example 1 acquisition of FGF21-TAT, FGF21-R11, FGF21-Fc Gene
TAT, R11 and Fc fragment of IgG are designed at 3' end of FGF21 gene, FGF-21 gene with cleavage sites BsaI and BamHI are designed at two ends, and three recombinant plasmids are synthesized by Shanghai Ind.
The newly synthesized FGF-21-TAT, FGF-21-R11 and FGF-21-Fc plasmids of Shanghai engineering and SUMO vectors stored in a laboratory were subjected to double digestion (100. Mu.L system) by restriction enzymes BsaI and BamHI, and the gel recovery products were ligated. After the reagents in the connection system are mixed uniformly, the connection is carried out in a metal water bath connector overnight. The following day, the ligation products were transferred into DH 5. Alpha. Competent cells by heat shock transformation, 200. Mu.L was plated on solid medium containing ampicillin resistance, incubated for 12-16h in a 37℃incubator, single colonies were picked up in 20mL of ampicillin resistant liquid medium in a sterile ultra-clean bench, and incubated overnight at 37℃in a shaker at 120 rpm. The vials were removed from the shaker and plasmids were extracted according to the plasmid extraction kit.
EXAMPLE 2 expression and preparation of fibroblast growth factor 21-TAT/R11/Fc
(1) Induction of expression
Three recombinant plasmids containing the correct sequences were transformed into the expression strain Rossetta (DE 3) (Shanghai Bowman Biotechnology Co., ltd., catalog number 130558-10). The transformed single colonies were inoculated into 5mL of LB medium containing ampicillin (100. Mu.g/mL), cultured at 37℃for 12 hours, inoculated into 500mL of LB medium containing ampicillin (100. Mu.g/mL) at 1:100, cultured at 37℃for 2 hours, induced by adding IPTG to a final concentration of 0.5mmol/L when A600=0.5, harvested after 4 hours, sonicated, centrifuged, and 15% SDS-PAGE analysis was performed on whole bacteria, supernatant and pellet, respectively. As a result, it was found that SUMO-FGF-21-R11 and SUMO-FGF-21-Fc were expressed as a target protein in a soluble form, and SUMO-FGF-21-TAT was expressed as a target protein in a precipitated form.
(2) Protein preparation
According to the optimal conditions for the expression of the fusion protein, the culture volume is enlarged, bacterial cells are collected after induced expression, SUMO-FGF-21-R11 and SUMO-FGF-21-Fc are crushed, supernatant is centrifugally collected, DEAE Sepharose FF is purified, and 25mmol/L Tris-HCl,0.25mol/L NaCl and pH8.0 are used for elution. Collecting the adsorption peak component, performing Ni.NTA resin affinity chromatography, balancing Ni.NTA resin with 50m mol/L Tris-HCl buffer solution, pH8.0,0.5 mol/LNaCl and 10m mol/L imidazole, draining the lysate to a well-balanced resin column, and washing with 50m mol/L Tris-HCl buffer solution, pH8.0,0.5mol/L NaCl and 50m mol/L imidazole after loading. Finally, 50m mol/L Tris-HCl buffer, pH8.0,0.5mol/L NaCl,500m mol/L imidazole was used to elute the target protein. The elution peaks were collected and examined by SDS-PAGE. The results showed that the band sizes of the purified FGF-21-R11, FGF-21-Fc proteins were consistent with the expected sizes.
SUMO-FGF-21-TAT is subjected to bacterial disruption and denaturation, the protein space structure is opened through denaturation of denaturation liquid (8 mol/L Urea,0.1mol/LNa2HPO4,0.01mol/L Tris, pH 7.5), so that the protein is dissolved in the denaturation liquid, the dissolved protein is slowly added dropwise into 10-time volume renaturation liquid (10 mmol/L Tris-buffer, pH 8.0) so that the final concentration reaches 1.0mg/mL, and the solution is dialyzed 3 times at 4 ℃ through PBS (pH 7.4) for 8 hours each time. The dialyzed proteins were concentrated using PEG8000, and the concentrated proteins were subjected to affinity chromatography, as described above, and the purified proteins were subjected to SDS-PAGE analysis. The results showed that the size of the purified FGF-21-TAT protein band was consistent with the expected size.
3. Activity detection of FGF21-TAT, FGF21-R11, FGF21-Fc protein
(1) Protein cell level activity assay
S9 cells were starved for 12h, purified FGF-21-TAT, FGF-21-R11, FGF-21-Fc protein was diluted with cell culture medium to a final concentration of 10, 100, 1000nmol/L, and dilutions of different concentrations were added to differentiated mature adipocytes at 1ml per well. At least 3 replicate wells were provided for each concentration.
Detection of glucose concentration: after incubating the cells for 24 hours in the above treatments, 2. Mu.L of the supernatant medium was placed in 200. Mu.L of a glucose test solution to determine the glucose content. Each concentration was repeated at least 3 times, and after 5 to 10 minutes of reaction at 37℃the OD value was measured at a wavelength of 500 nm. The glucose consumption rate of the cells was calculated as follows, and the experimental results were analyzed using statistics.
And calculating the concentration of the residual glucose in the culture solution, wherein the formula is as follows:
Glucose concentration (mmol/L) =OD Sample of /OD Standard of X5.55 mmol/L
The consumption rate of the cells on glucose is calculated, and the formula is as follows:
cell glucose consumption (%) = [ (C Blank glucose -C Administration of glucose )/C Blank glucose ] ×100%).
After S9 cells are treated for 24 hours by FGF-21 proteins with different concentrations, the glucose content in the culture medium is detected by a glucose detection kit of a micro-GOD-POD method, and the statistical analysis result shows that three FGF-21 proteins can obviously promote the glucose absorption level of the cells, thereby indicating that the three FGF-21 proteins have better biological activity.
(2) In vivo Activity assay of FGF-21 protein
C57BL/6J mice were purchased from Gibbs laboratory animal technology Co., ltd, and the laboratory mice were randomly divided into 4 groups of 5 mice each. 20C 57BL/6 mice are intraperitoneally injected with 80mg/kg Streptozotocin (STZ), a diabetes model is established, the successfully modeled diabetes model mice are selected and randomly divided into a model group, an FGF-21-TAT group, an FGF-21-R11 group and an FGF-21-Fc group, 5 mice in each group are used, and a blank control group (n=5) is established. Mice in the FGF-21-TAT group, the FGF-21-R11 group and the FGF-21-Fc group are subjected to intraperitoneal injection of three FGF-21 proteins at a dose of 1mg/kg every day under the conditions of no fasting and no water, and the continuous injection is carried out for 7 days; normal and model mice were injected daily with physiological saline for 7 days. Early 8 a day: 00 injections and blood glucose measurements prior to administration
The results show that after 7 days of treatment by three FGF-21 proteins, the blood sugar of the mice is obviously reduced compared with that of a model group, the blood sugar level of the model group is continuously increased, and the blood sugar reaches 27.3+/-0.25 mmol/L after the experiment is finished; the blood sugar of the mice continuously decreases after being treated by the FGF-21 protein, the blood sugar of the mice in the FGF-21-TAT group decreases from 20.2+/-0.37 mmol/L to 13.6+/-0.16 mmol/L, the blood sugar of the mice in the FGF-21-R11 group decreases from 19.8+/-0.31 mmol/L to 13.8+/-0.15 mmol/L, and the blood sugar of the mice in the FGF-21-Fc group decreases from 20.9+/-0.26 mmol/L to 13.6+/-0.24 mmol/L, compared with the model group, the blood sugar is obviously decreased (p < 0.01), which indicates that the biological activity of the FGF-21-TAT, FGF-21-R11 and FGF-21-Fc proteins is good, and the mice can be used for subsequent experiments.
EXAMPLE 3 investigation of the Effect of FGF21-TAT/R11/Fc on improving atopic dermatitis
1. Atopic dermatitis mouse model establishment and treatment
48 Female Balb/c mice of SPF class 6-8 weeks old were randomly divided into 6 groups of 8: normal control, model, FGF-21-TAT, FGF-21-R11, FGF-21-Fc, and positive drug (Tacrolimus Tacrolimus). Mixing with acetone and olive oil (3:1) to obtain matrix solution, and diluting chemical hapten 1-chloro-2,4 dinitrobenzene (1-chloro-2, 4-dinitratenzene, DNCB) into 1% DNCB and 0.5% DNCB. The back hair of the mice was removed 24h before molding using depilatory cream. In the mould sensitization stage, at week 1, sucking 150 mu L of 1% DNCB solution prepared by matrix liquid (acetone/olive oil=3:1) by using a micropipette every 2 days, multi-point coating on the back dehairing place of a mouse, uniformly coating by using a sterile cotton swab, point-coating 50 mu L of 1% DNCB solution on the inner and outer surfaces of the right ear of the experimental mouse, and coating 50 mu L of DNCB-free matrix liquid on the left ear; the matrix liquid is smeared on the back and the right ear of the normal mice. Sucking 150 μl of 0.5% DNCB solution prepared from matrix solution (acetone/olive oil=3:1) by using a micropipette every 2 days in week 2-4, applying to the back dehairing place of the mice at multiple points, uniformly applying with a sterile cotton swab, and applying 50 μl of 0.5% DNCB solution to the inner and outer surfaces of the right ear of the experimental mice at points, and applying 50 μl of DNCB-free matrix solution to the left ear; the matrix liquid is smeared on the back and the right ear of the normal mice. On weeks 2-4, mice were treated, groups of FGF-21-TAT, FGF-21-R11, FGF-21-Fc were given intraperitoneal injections of FGF-21-TAT, FGF-21-R11, FGF-21-Fc protein (1 mg/kg) each every two days, model groups were given equal amounts of PBS, positive group (Tacrolimus) mice were coated with 0.02mg Tacrolimus ointment, and the normal groups were not treated.
2. Related dermatitis index detection
During the molding process, mice were evaluated for back skin lesions prior to each sensitization. Skin lesion severity was estimated by 4 symptoms, edema; erythema/hemorrhage; peeling off the epidermis; scale/drying; lichenification, each clinical symptom was scored in half, i.e., 0.5 points, on a scale of 0 (none), 1 (mild), 2 (moderate) and 3 (severe) between the scores of each symptom. The scoring principle is 0 score, namely that no sign appears; 1 minute, the sign exists, but the sign can be seen through careful observation; 2 minutes, the sign can be seen immediately; 3 minutes, the sign is very obvious. Three observers outside the experiment independently observe and aggregate the symptom scores for each mouse with the above scores as criteria. Before each sensitization, the body weight of the mice was measured by a balance and the ear thickness of the mice was measured by a micrometer thickness gauge, including the thickness of the left ear (non-sensitization) and the thickness of the right ear (sensitization), the difference value (difference value=thickness of the right ear-thickness of the left ear) was taken after each measurement, and the ear swelling degree of the mice was evaluated and compared by statistical analysis. Dermatitis scoring results show that after sensitization for 7 days, the back skin of each group of mice has erythema, edema, scars and lichen lesions, which accords with the symptoms of atopic dermatitis. The dermatitis score was significantly reduced on day 14 for the FGF-21-R11 group (p < 0.05), compared to the model group, the dermatitis score was significantly reduced on day 14 for the FGF-21-Fc group (p < 0.01), compared to the FGF-21-TAT group, the dermatitis score was significantly reduced on day 14 (p < 0.05); there was no significant difference in dermatitis scores (p > 0.05) on day 28 during treatment of FGF-21-TAT, FGF-21-R11, and FGF-21-Fc groups compared to Tacrolimus. Ear thickness measurements showed that the ear swelling levels of mice in groups FGF-21-TAT, FGF-21-R11, FGF-21-Fc were significantly reduced (p < 0.01) on days 24 and 28, and that the ear swelling levels of mice in group FGF-21-R11 were significantly reduced (p < 0.05) on day 20 compared to Tacrolimus. The three proteins are shown to have better therapeutic effect on relieving ear swelling than Tacrolimus.
3. Histopathological detection
After the experiment, the mice were bled in EP tubes and allowed to stand at 4℃for 30 minutes and centrifuged at 3500r/min at 4℃for 15 minutes. The pipette aspirates serum into the EP tube and stores at-80 ℃. Wrapping a part of back skin and ear tissue of a mouse with tinfoil, and storing at-80deg.C; the other part is put into 4% paraformaldehyde (PBS for preparation), and the mixture is sealed and fixed for more than 48 hours at room temperature. The fixed tissue is trimmed into tissue blocks with the thickness of 2-3mm and the area of 1X 1cm 2, and the tissue blocks are placed in an embedding box, are washed for more than 12 hours by tap water, and are dehydrated, transparent, waxed and embedded after paraformaldehyde is removed, so that tissue sections are manufactured. The tissue sections were subjected to H & E staining and immunohistochemistry.
4. Related cytokine detection
The protein expression levels of IL-1 beta, IL-4, IL-13, IL-17A, IFN-gamma, TNF-alpha and total IgE in the serum of mice were detected by ELISA kit.
Claims (1)
1. The canine fibroblast growth factor 21 fusion protein shown in the sequence 3 or a coding gene thereof or an expression cassette containing the coding gene, a recombinant vector, a transgenic cell line or recombinant bacteria are applied to the preparation of products; the product has the following function (I) and is used for treating canine atopic dermatitis.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410732073.3A CN118530374A (en) | 2023-06-02 | 2023-06-02 | Preparation of canine fibroblast growth factor 21 fusion protein and application thereof in treating atopic dermatitis |
CN202410732069.7A CN118496383A (en) | 2023-06-02 | 2023-06-02 | Preparation of canine fibroblast growth factor 21 fusion protein and application thereof in treating atopic dermatitis |
CN202310648161.0A CN116675780B (en) | 2023-06-02 | 2023-06-02 | Preparation of canine fibroblast growth factor 21 fusion protein and application thereof in treating atopic dermatitis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310648161.0A CN116675780B (en) | 2023-06-02 | 2023-06-02 | Preparation of canine fibroblast growth factor 21 fusion protein and application thereof in treating atopic dermatitis |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410732069.7A Division CN118496383A (en) | 2023-06-02 | 2023-06-02 | Preparation of canine fibroblast growth factor 21 fusion protein and application thereof in treating atopic dermatitis |
CN202410732073.3A Division CN118530374A (en) | 2023-06-02 | 2023-06-02 | Preparation of canine fibroblast growth factor 21 fusion protein and application thereof in treating atopic dermatitis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116675780A CN116675780A (en) | 2023-09-01 |
CN116675780B true CN116675780B (en) | 2024-07-09 |
Family
ID=87783043
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410732069.7A Pending CN118496383A (en) | 2023-06-02 | 2023-06-02 | Preparation of canine fibroblast growth factor 21 fusion protein and application thereof in treating atopic dermatitis |
CN202410732073.3A Pending CN118530374A (en) | 2023-06-02 | 2023-06-02 | Preparation of canine fibroblast growth factor 21 fusion protein and application thereof in treating atopic dermatitis |
CN202310648161.0A Active CN116675780B (en) | 2023-06-02 | 2023-06-02 | Preparation of canine fibroblast growth factor 21 fusion protein and application thereof in treating atopic dermatitis |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410732069.7A Pending CN118496383A (en) | 2023-06-02 | 2023-06-02 | Preparation of canine fibroblast growth factor 21 fusion protein and application thereof in treating atopic dermatitis |
CN202410732073.3A Pending CN118530374A (en) | 2023-06-02 | 2023-06-02 | Preparation of canine fibroblast growth factor 21 fusion protein and application thereof in treating atopic dermatitis |
Country Status (1)
Country | Link |
---|---|
CN (3) | CN118496383A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105348380A (en) * | 2015-12-28 | 2016-02-24 | 哈尔滨博翱生物医药技术开发有限公司 | CFGF21 (canine fibroblast growth factor 21) and application of cFGF21 to treatment of canine endocrine diseases |
CN106892982A (en) * | 2017-04-05 | 2017-06-27 | 东北农业大学 | Novel fusion polypeptide and its application of targeting IL 17 and TNF α |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107188950B (en) * | 2009-05-05 | 2021-09-28 | 安姆根有限公司 | FGF21 mutant and application thereof |
AU2016218977C1 (en) * | 2015-02-13 | 2023-03-23 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
BR112022008610A2 (en) * | 2019-11-05 | 2022-08-09 | Dermira Inc | TOPICAL COMPOSITIONS INCLUDING IRAK4 INHIBITORS FOR USE IN TREATMENT OF DERMATOLOGICAL CONDITIONS CHARACTERIZED BY INFLAMMATION |
-
2023
- 2023-06-02 CN CN202410732069.7A patent/CN118496383A/en active Pending
- 2023-06-02 CN CN202410732073.3A patent/CN118530374A/en active Pending
- 2023-06-02 CN CN202310648161.0A patent/CN116675780B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105348380A (en) * | 2015-12-28 | 2016-02-24 | 哈尔滨博翱生物医药技术开发有限公司 | CFGF21 (canine fibroblast growth factor 21) and application of cFGF21 to treatment of canine endocrine diseases |
CN106892982A (en) * | 2017-04-05 | 2017-06-27 | 东北农业大学 | Novel fusion polypeptide and its application of targeting IL 17 and TNF α |
Non-Patent Citations (2)
Title |
---|
"利用1型糖尿病小鼠模型分析犬成纤维生长因子21的长效降糖效果";郭云鹏 等;《畜牧兽医学报》;20231218;第1-23页 * |
Tang,L.等."immunoglobulin gamma heavy chain D [Canis lupus familiaris]".《genbank》.2001,ACCESSION AAL35304. * |
Also Published As
Publication number | Publication date |
---|---|
CN116675780A (en) | 2023-09-01 |
CN118496383A (en) | 2024-08-16 |
CN118530374A (en) | 2024-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110845603B (en) | Human collagen 17-type polypeptide, production method and use thereof | |
US10400229B2 (en) | Bacterial hyaluronidase and process for its production | |
CN114599667B (en) | Keratin BD-1, its preparation method, its pharmaceutical composition and use | |
CN116675780B (en) | Preparation of canine fibroblast growth factor 21 fusion protein and application thereof in treating atopic dermatitis | |
DE69333185T2 (en) | DNA ENCODING CHITINE DEACETYLASE | |
DE3886395T2 (en) | BEEF INTERLEUKIN 1 g (b). | |
CN109954004B (en) | Application of bacteroides fragilis extract in preparation of composition for preventing and treating psoriasis | |
CN1982457A (en) | Toxic sequential, its preparation and use | |
CN108949730A (en) | A kind of preparation method and applications recombinating allosteric clostridiopetidase A | |
CN114195875B (en) | Placenta-derived endogenous polypeptide and application thereof | |
CN101570760B (en) | Recombinant mouse beta-alexin 3 polypeptide, preparation and use thereof | |
CN114599672B (en) | Keratin BD-11, its preparation method, its pharmaceutical composition and use | |
US20050232913A1 (en) | Short chain neurotoxin from sea snake-lapemis hardwickii and genes encoding the neurotoxin | |
CN113603762A (en) | Cervus elaphus hybrid deer antler plate active peptide and preparation method and application thereof | |
CN112316117B (en) | Application of recombinant protein hID2 in preparation of colitis treatment drug | |
TWI309238B (en) | Protein and nucleic acid for glutathione-dependent formaldehyde dehydrogenase (gfd), alcohol dehydrogenase and s-nitrosoglutathione reductase from antrodia camphorata, manufacturing method and uses therefor | |
JP7402977B2 (en) | Keratin BD-4, its preparation and pharmaceutical compositions and uses | |
EP2217262B1 (en) | C-terminal ifapsoriasin fragments as antimicrobial peptides for use in the treatment of pseudomonas infections | |
CN114599668B (en) | Keratin BD-3, its preparation method, its pharmaceutical composition and use | |
KR100315929B1 (en) | Novel Polypeptides and DNA Encoding Dipeptides | |
RU2289623C2 (en) | HUMAN PLASMIDE pBSH2EGF DNA ENCODING SYNTHESIS OF HUMAN EPIDERMAL GROWTH FACTOR AND METHOD FOR PRODUCTION WHEREOF USING THE SAME | |
DE102024101586A1 (en) | CLOSTRIDIUM BOTULINUM SEROTYPE A NEUROTOXIN (BONT/A) SEQUENCE VARIANTS | |
CN113117047A (en) | Polypeptide anti-inflammatory and itching-relieving composition | |
CN118324930A (en) | Recombinant humanized lactoferrin and preparation method thereof | |
CN117305277A (en) | Novel glycosidase for degrading acarbose and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |